What sense does step therapy make for someone with severe osteoporosis since the other drugs don’t build bone and is there any way to get Medicare to go directly to allowing bone building meds

Step therapy is a cost-control gate, not a clinical plan, and for severe osteoporosis it forces you through drugs that only slow bone loss before letting you reach the ones that actually build bone.

The evidence is clear that anabolic drugs (teriparatide, abaloparatide, romosozumab) are the most effective at reducing fractures in severe disease [3][6]. In a head-to-head trial, teriparatide cut new vertebral fractures to about 5 in 100 people versus 12 in 100 on risedronate over two years [5]. A meta-analysis found teriparatide roughly halved vertebral fracture risk compared to bisphosphonates [4]. The catch: anabolics are expensive, so insurers and Medicare drug plans impose step therapy to force cheaper antiresorptives first.

There is a legitimate clinical reason for sequencing, but it runs the opposite direction. Guidelines recommend anabolics first for the highest-risk patients, then a bisphosphonate or denosumab afterward to maintain the bone gained [2][3]. Using an antiresorptive first actually blunts the anabolic response [1][2]. So step therapy here is not just annoying; it can make the eventual anabolic less effective.

On Medicare: Part D plans can require step therapy, but you can request a coverage determination and an exception. Your doctor must document severe osteoporosis, high fracture risk, and why antiresorptives are inappropriate or insufficient. Prior fractures, very low T-scores, and contraindications to bisphosphonates (like kidney problems) strengthen the case. If denied, you can appeal through the plan's internal process, then to independent review. Medicare Advantage plans have similar rules. The key is a doctor willing to fight the paperwork.

My call: step therapy for severe osteoporosis is clinically backwards and financially motivated, but you can bypass it with a documented exception request and appeals. Confidence: high on the clinical evidence, moderate on the Medicare process since the retrieved records do not cover coverage rules.